The S&P/ASX 200 (INDEXASX: ^AXJO) (ASX: XJO) rose slightly higher today, up 0.8% to 5,042 points despite a wobbly banking sector keeping investors nervous.
These four shares all rose significantly further however, and here's why:
Ziptel Ltd (ASX: ZIP) soared 14% to $0.365 after the company announced that its brand ambassador campaign had resulted in a significant uplift in installs. Ziptel now has 10 million installations, with the most recent 2 million coming in the past four weeks. This level of installs comes some nine months ahead of company forecasts and means that Ziptel can now focus on monetising its services.
With just $2.7 million in cash as at 31 December 2015 and heavy cash outflows, Ziptel will likely have to source additional capital to continue with its expansion plans. However, the whole company is valued at just $21m and, down 39% for the year, it is an interesting prospect today.
Pro Medicus Limited (ASX: PME) jumped 10% to $3.76 on news that the company had landed a A$21m+, 7-year deal with Mercy Health in the US, who will license the company's Vision 7 technology for diagnosis of medical images. The deal could be the first of several with Mercy, which is the major shareholder in a healthcare supply chain business. It's no surprise shareholders are excited, with today's 10% rise carrying Pro Medicus' shares up 145% for the year.
Freelancer Ltd (ASX: FLN) rose 5% to $1.27 on no news, after a period of heavy selling following the company's most recent quarterly report. Possibly a slowdown in sales was to blame, with the $11m in revenue earned representing 30% of the revenue made in the past three quarters. If growth was accelerating, investors might expect this figure to be greater than 30%. However, Freelancer continues to deliver positive operating cash flow, and with $32m in the bank is extremely well funded to continue investing in itself and making acquisitions.
Freelancer shares are up 32% in the past 12 months.
Medical Developments International Ltd (ASX:MVP) leapt 10% to $5.81 on no news as investor expectations mount regarding the company's ongoing expansion and recent entry into the ALL ORDINARIES (ASX: ^AXAO) (ASX: XAO) index. The company's latest report wasn't particularly remarkable, but with approval in 11 markets for its Penthrox product and a number of additional approvals pending, Medical Development's growth is all ahead of it. Given the size of Medical Development's target markets and the potential to take market share from narcotic painkillers, available growth certainly appears to be significant. However, much growth appears already priced in to the company.
Medical Developments shares are up 153% for the year.
